it's a treatment for hypoparathyroidism.will give you a 238% gain since it was first recommended a year ago and up since the last march and after that move maybe you're being too greedy and maybe you should ring the register? i don't know. half, two-thirds? what about the rest? let's check in with dr. francois nadir, the president and ceo of mps to find out how the company is doing and where it's headed. welcome back to the show. >> good to see you. >> some people say, jim, you got behind this company and it's $2.8 billion and they have 300, some-odd prescriptions. you're crazy, and i -- i come back and say, why don't you listen to tonight, because you'll realize that there is a big pipeline within this pipeline. >> exactly right. so we were phenomenally happy with the launch in the u.s. we are fighting hypoparathyroidism by the end of this year and by the end of next year and we went global as of march and we're build our international expansion and hopefully we'll have sales in europe early next year and we'll have a pipel